Evidence map›Paper›PMID 32886278›Full record

ArticleInternational journal of hematology2020

Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma.

Yasuhiro Suzuki, Takahiro Yano, Youko Suehiro, Hiromi Iwasaki, Michihiro Hidaka, Maki Otsuka, Kazutaka Sunami, Hirokazu Ikeda, Morio Sawamura, Takuo Ito and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Yasuhiro SuzukiDepartment of Hematology, National Hospital Organization Nagoya Medical Center, 4-1-1, Sannomaru, Naka-ku, Nagoya, 460-0001, Japan. yassuzuki@med.nagoya-u.ac.jp.ORCID http://orcid.org/0000-0002-1108-4540
Takahiro YanoDepartment of Hematology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Youko SuehiroDepartment of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Hiromi IwasakiDepartment of Hematology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Michihiro HidakaDepartment of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
Maki OtsukaDepartment of Hematology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan.
Kazutaka SunamiDepartment of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.
Hirokazu IkedaDepartment of Hematology, National Hospital Organization Osaka Medical Center, Osaka, Japan.
Morio SawamuraDepartment of Hematology, National Hospital Organization Shibukawa Medical Center, Shibukawa, Japan.
Takuo ItoDepartment of Hematology, National Hospital Organization Kure Medical Center, Kure, Japan.
Hiroatsu IidaDepartment of Hematology, National Hospital Organization Nagoya Medical Center, 4-1-1, Sannomaru, Naka-ku, Nagoya, 460-0001, Japan.
Hirokazu NagaiDepartment of Hematology, National Hospital Organization Nagoya Medical Center, 4-1-1, Sannomaru, Naka-ku, Nagoya, 460-0001, Japan.
National Hospital Organization · JPKumamoto Medical Center · JPNational Hospital Organization Kyushu Cancer Center · JPNational Kyushu Medical Center · JPOsaka National Hospital · JPTokyo Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, progression of disease within 24 months (POD24) has been demonstrated as a strong prognostic indicator in various types of malignant lymphoma. Peripheral T-cell lymphoma (PTCL) has an aggressive course and poor clinical outcomes. In this multicenter retrospective study, 111 consecutively registered patients with newly diagnosed PTCL were analyzed. Of these patients, 72 (64.9%) experienced POD24 (POD24 group), and the other 39 patients (35.1%) were analyzed as the no POD24 group. In the POD24 group, overall survival (OS) was significantly inferior to all patients, and in the no POD24 group, subsequent OS was significantly superior to the POD24 group, although the clinical characteristics between the POD24 group and no POD24 group were not significantly different. Twenty-three patients (20.7%) showed primary refractory disease to first-line therapy, and the prognosis was poor. The International Prognostic Index score and POD24 were identified as independent predictors in multivariate analysis for OS in all patients, and only performance status was an independent prognostic factor for OS in the POD24 group in multivariate analysis. In conclusion, the clinical significance of assessing POD24 in PTCL and the poor prognosis in patients with early disease progression were demonstrated.

Indexed as

Research DesignAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDisease ProgressionFemaleHumansLymphoma, T-Cell, PeripheralMaleMiddle AgedMulticenter Studies as TopicPrognosisRetrospective StudiesStem Cell TransplantationClinical practiceEarly disease progressionNon-Hodgkin lymphomaPeripheral T-cell lymphomaPOD24

Identifiers

PMID32886278
OpenAlexW3083197585

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.